UY32142A - Preparación de una quinoliniloxidifenilciclopropanodicarboxamida - Google Patents

Preparación de una quinoliniloxidifenilciclopropanodicarboxamida

Info

Publication number
UY32142A
UY32142A UY0001032142A UY32142A UY32142A UY 32142 A UY32142 A UY 32142A UY 0001032142 A UY0001032142 A UY 0001032142A UY 32142 A UY32142 A UY 32142A UY 32142 A UY32142 A UY 32142A
Authority
UY
Uruguay
Prior art keywords
preparation
quinoliniloxidifenilciclopropanodicarboxamida
compound
relates
present
Prior art date
Application number
UY0001032142A
Other languages
English (en)
Inventor
Zhou Xiaoming
Nicole Marie Deschamps
Michael Tolar Martin
Michael John Monteith
Original Assignee
Smithkline Beckman Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beckman Corp filed Critical Smithkline Beckman Corp
Publication of UY32142A publication Critical patent/UY32142A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a un procedimiento para preparar un compuesto de la fórmula III siguiente: en el que R1-R4 son como se define en la presente memoria. La presente invención también se refiere a la preparación de compuestos intermedios usados para preparar el compuesto de fórmula III:
UY0001032142A 2008-09-26 2009-09-24 Preparación de una quinoliniloxidifenilciclopropanodicarboxamida UY32142A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10045208P 2008-09-26 2008-09-26

Publications (1)

Publication Number Publication Date
UY32142A true UY32142A (es) 2010-05-31

Family

ID=42058136

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032142A UY32142A (es) 2008-09-26 2009-09-24 Preparación de una quinoliniloxidifenilciclopropanodicarboxamida

Country Status (8)

Country Link
US (1) US8314232B2 (es)
EP (1) EP2339918A4 (es)
JP (1) JP5587324B2 (es)
CN (1) CN102227164A (es)
AR (1) AR075084A1 (es)
TW (1) TW201035017A (es)
UY (1) UY32142A (es)
WO (1) WO2010036831A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2599458T3 (es) 2008-10-14 2017-02-01 Sunshine Lake Pharma Co., Ltd. Compuestos y métodos de uso
NZ779754A (en) 2009-01-16 2023-04-28 Exelixis Inc Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl] oxy} phenyl)-n’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
EP2408300B1 (en) 2009-03-21 2016-05-11 Sunshine Lake Pharma Co., Ltd. Amino ester derivatives, salts thereof and methods of use
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
SG185073A1 (en) 2010-04-29 2012-12-28 Deciphera Pharmaceuticals Llc Cyclopropyl dicarboxamides and analogs exhibiting anti-cancer and anti-proliferative activites
EA030435B1 (ru) 2010-07-16 2018-08-31 Экселиксис, Инк. ТАБЛЕТКА, СОДЕРЖАЩАЯ МОДУЛЯТОР c-MET В ФОРМЕ КРИСТАЛЛИЧЕСКОЙ L-МАЛАТНОЙ СОЛИ (ВАРИАНТЫ), СПОСОБ ЕЕ ПРОИЗВОДСТВА И СПОСОБ ЛЕЧЕНИЯ ОНКОЛОГИЧЕСКОГО ЗАБОЛЕВАНИЯ С ЕЕ ИСПОЛЬЗОВАНИЕМ
MX352926B (es) 2010-09-27 2017-12-14 Exelixis Inc Inhibidores dobles de met y factor de crecimiento endotelial vascular (vegf) para el tratamiento de cancer de prostata resistente a la castracion y metastasis osteoblasticas en los huesos.
BR112013020362A2 (pt) 2011-02-10 2018-05-29 Exelixis Inc processos para a preparação de compostos de quinolina, compostos e combinações farmacêuticas que os contem
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
MX2013012695A (es) 2011-05-02 2014-03-27 Exelixis Inc Metodo para el tratamiento del cancer y el dolor por cancer de hueso.
EP2758057B1 (en) 2011-09-22 2017-05-31 Exelixis, Inc. Method for treating osteoporosis
CN104395284A (zh) * 2011-10-20 2015-03-04 埃克塞里艾克西斯公司 制备喹啉衍生物的方法
WO2013166296A1 (en) 2012-05-02 2013-11-07 Exelixis, Inc. A dual met - vegf modulator for treating osteolytic bone metastases
CN103664776B (zh) * 2012-09-26 2016-05-04 正大天晴药业集团股份有限公司 一种酪氨酸激酶抑制剂及其中间体的制备方法
CN102977014B (zh) 2012-11-05 2015-01-07 沈阳药科大学 新的喹啉类化合物及其用途
CN102964308B (zh) * 2012-11-30 2015-03-18 中国药科大学 新型嘧啶类化合物、其制备方法、包含此类化合物的药物组合物及其用途
CN103044263A (zh) * 2013-01-14 2013-04-17 中国药科大学 一种治疗囊性纤维化药物的中间体的制备方法
CN103965104B (zh) * 2013-01-29 2017-09-29 正大天晴药业集团股份有限公司 一种酪氨酸激酶抑制剂及其中间体的制备方法
CA2907334C (en) 2013-03-15 2021-12-07 Exelixis, Inc. Metabolites of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
US11564915B2 (en) 2013-04-04 2023-01-31 Exelixis, Inc. Cabozantinib dosage form and use in the treatment of cancer
BR112016018450A2 (pt) 2014-02-14 2018-09-18 Exelixis Inc formas sólidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida, processos de preparo e métodos de uso
EP3119476A1 (en) 2014-03-17 2017-01-25 Exelixis, Inc. Dosing of cabozantinib formulations
EP3174854B1 (en) 2014-07-31 2022-08-24 Exelixis, Inc. Method of preparing fluorine-18 labeled cabozantinib and its analogs
MX382904B (es) 2014-08-05 2025-03-13 Exelixis Inc Combinaciones de fármacos para tratar mieloma múltiple.
CN105218445B (zh) * 2015-08-25 2018-05-22 江苏中邦制药有限公司 一种酪氨酸激酶抑制剂Foretinib的制备方法
EP3442531A1 (en) 2016-04-15 2019-02-20 Exelixis, Inc. Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
CN110117254B (zh) * 2019-06-20 2022-05-13 江苏君若药业有限公司 卡博替尼的制备方法
CN112194622A (zh) * 2020-09-24 2021-01-08 上海毕得医药科技有限公司 一种5-氯喹啉-4-醇的合成方法
US20260049059A1 (en) 2022-11-25 2026-02-19 Synthon B.V. A process for preparation of cabozantinib or tivozanib

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2210607B1 (en) * 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
JP2007518823A (ja) * 2004-01-23 2007-07-12 アムゲン インコーポレイテッド キノリン、キナゾリン、ピリジン、及びピリミジン化合物と炎症、血管新生、及び癌に対する治療におけるそれら化合物の用途

Also Published As

Publication number Publication date
US8314232B2 (en) 2012-11-20
CN102227164A (zh) 2011-10-26
WO2010036831A1 (en) 2010-04-01
EP2339918A1 (en) 2011-07-06
US20100081805A1 (en) 2010-04-01
JP5587324B2 (ja) 2014-09-10
AR075084A1 (es) 2011-03-09
TW201035017A (en) 2010-10-01
JP2012503671A (ja) 2012-02-09
EP2339918A4 (en) 2012-06-06

Similar Documents

Publication Publication Date Title
UY32142A (es) Preparación de una quinoliniloxidifenilciclopropanodicarboxamida
IN2012DN02751A (es)
CU20110052A7 (es) Compuestos orgánicos
MX377930B (es) Proceso para fabricar compuestos de quinolona.
HN2011000341A (es) Compuestos derivados de sulfonamidas, composiciones farmaceuticos y proceso de preparacion de los mismos
UY31367A1 (es) Derivados de nicotinamida, su preparacion y su aplicacion en terapeutica
CU24354B1 (es) Procedimiento de obtención de derivados de tetrafluoropropilmorfolina
ECSP10010434A (es) Inhibidores de hsp90
MX2020010330A (es) Proceso para preparar un compuesto antiviral de formula i.
CO6771439A2 (es) Inhibidores de benzodioxano de la producción de leucotrieno
NI201100078A (es) Proceso para la preparación de derivados de l-alanina protegidos.
EP2590649A4 (en) PROCESS FOR SYNTHESIS OF SUBSTITUTED MORPHINANES
UY32517A (es) Derivados de nicotinamida, su preparación y su aplicación en terapéutica
BR122018074319B8 (pt) Método para preparar um composto de fórmula 14
MX2012001411A (es) Proceso para la preparacion de derivados de acido 1-(2-halobifenil-4-il)-ciclopropanocarboxilico.
CR20120592A (es) Intermedios de agomelatina y métodos de preparación de estos
MY164880A (en) Process for the preparation of isoxazolyl-methoxy-nicotinic acids
CR20110208A (es) Proceso para la preparación de benzonorbornenos
CY1119697T1 (el) Μεθοδος παρασκευης ενωσεων α-γαλακτοζυλο κεραμιδιων
MX2010009926A (es) Nuevo proceso para la preparacion de derivados de acido ciclohexancarboxilico.
MX2020009462A (es) Procesos para la preparación de compuestos de pirimidinilciclopentano.
UY35766A (es) Proceso industrial para la síntesis de ingredientes activos esteroides
MX2013004193A (es) Procedimiento para la preparacion de derivados de acido 3-(6-amino-piridin-3-il)-2-acrilico.
BR112012008952A2 (pt) microbicidas
MX2013002656A (es) Nuevo proceso.

Legal Events

Date Code Title Description
104 Application deemed to be withdrawn (no substantive examination fee paid)

Effective date: 20101124